First Indian report on genome-wide comparison of multidrug-resistant Escherichia coli from blood stream infections.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
07
2019
accepted:
07
02
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
28
4
2020
Statut:
epublish
Résumé
Multidrug-resistant (MDR) E. coli with extended-spectrum β-lactamases (ESBLs) is becoming endemic in health care settings around the world. Baseline data on virulence and antimicrobial resistance (AMR) of specific lineages of E. coli circulating in developing countries like India is currently lacking. Whole-genome sequencing was performed for 60 MDR E. coli isolates. The analysis was performed at single nucleotide polymorphism (SNP) level resolution to identify the presence of their virulence and AMR genes. Genome comparison revealed the presence of ST-131 global MDR and ST410 as emerging-MDR clades of E. coli in India. AMR gene profile for cephalosporin and carbapenem resistance differed between the clades. Genotypes blaCTX-M-15 and blaNDM-5 were common among cephalosporinases and carbapenemases, respectively. For aminoglycoside resistance, rmtB was positive for 31.7% of the isolates, of which 95% were co-harboring carbapenemases. In addition, the FimH types and virulence gene profile positively correlated with the SNP based phylogeny, and also revealed the evolution of MDR clones among the study population with temporal accumulation of SNPs. The predominant clone was ST167 (blaNDM lineage) followed by ST405 (global clone ST131 equivalent) and ST410 (fast spreading high risk clone). This is the first report on the whole genome analysis of MDR E. coli lineages circulating in India. Data from this study will provide public health agencies with baseline information on AMR and virulent genes in pathogenic E. coli in the region.
Sections du résumé
BACKGROUND
Multidrug-resistant (MDR) E. coli with extended-spectrum β-lactamases (ESBLs) is becoming endemic in health care settings around the world. Baseline data on virulence and antimicrobial resistance (AMR) of specific lineages of E. coli circulating in developing countries like India is currently lacking.
METHODS
Whole-genome sequencing was performed for 60 MDR E. coli isolates. The analysis was performed at single nucleotide polymorphism (SNP) level resolution to identify the presence of their virulence and AMR genes.
RESULTS
Genome comparison revealed the presence of ST-131 global MDR and ST410 as emerging-MDR clades of E. coli in India. AMR gene profile for cephalosporin and carbapenem resistance differed between the clades. Genotypes blaCTX-M-15 and blaNDM-5 were common among cephalosporinases and carbapenemases, respectively. For aminoglycoside resistance, rmtB was positive for 31.7% of the isolates, of which 95% were co-harboring carbapenemases. In addition, the FimH types and virulence gene profile positively correlated with the SNP based phylogeny, and also revealed the evolution of MDR clones among the study population with temporal accumulation of SNPs. The predominant clone was ST167 (blaNDM lineage) followed by ST405 (global clone ST131 equivalent) and ST410 (fast spreading high risk clone).
CONCLUSIONS
This is the first report on the whole genome analysis of MDR E. coli lineages circulating in India. Data from this study will provide public health agencies with baseline information on AMR and virulent genes in pathogenic E. coli in the region.
Identifiants
pubmed: 32101543
doi: 10.1371/journal.pone.0220428
pii: PONE-D-19-19739
pmc: PMC7043739
doi:
Substances chimiques
Carbapenems
0
Cephalosporins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0220428Subventions
Organisme : Department of Health
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29439957
mSphere. 2018 Jul 18;3(4):
pubmed: 30021879
Antimicrob Agents Chemother. 2014 Dec;58(12):7548-52
pubmed: 25246393
Mol Microbiol. 2006 Sep;61(6):1556-68
pubmed: 16930149
Int J Antimicrob Agents. 2018 Aug;52(2):278-282
pubmed: 29596903
Infect Dis Clin North Am. 2016 Jun;30(2):523-537
pubmed: 27208771
Clin Microbiol Infect. 2014 Jun;20(6):O344-52
pubmed: 24118431
J Antimicrob Chemother. 2008 Feb;61(2):273-81
pubmed: 18077311
Diagn Microbiol Infect Dis. 2009 May;64(1):57-63
pubmed: 19232867
Sci Rep. 2018 Jan 10;8(1):390
pubmed: 29321680
Antimicrob Agents Chemother. 2014;58(2):1146-52
pubmed: 24323475
J Antimicrob Chemother. 2010 Apr;65(4):651-60
pubmed: 20118165
Sci Rep. 2015 Jul 21;5:12275
pubmed: 26194736
BMC Infect Dis. 2015 Jun 09;15:224
pubmed: 26054866
Biomed Res Int. 2014;2014:959206
pubmed: 24895634
Indian J Med Res. 2019 Feb;149(2):222-231
pubmed: 31219087
Nucleic Acids Res. 2015 Feb 18;43(3):e15
pubmed: 25414349
J Clin Microbiol. 2003 Jun;41(6):2348-57
pubmed: 12791848
Emerg Infect Dis. 2007 Jun;13(6):838-46
pubmed: 17553221
J Infect Public Health. 2018 May - Jun;11(3):347-351
pubmed: 29107607
Southeast Asian J Trop Med Public Health. 2014 Jan;45(1):113-22
pubmed: 24964660
J Antimicrob Chemother. 2006 Jul;58(1):211-5
pubmed: 16720567
J Infect. 2008 Dec;57(6):441-8
pubmed: 18990451
Bioinformatics. 2015 Nov 15;31(22):3691-3
pubmed: 26198102
Indian J Exp Biol. 2016 Feb;54(2):108-14
pubmed: 26934778
Antimicrob Agents Chemother. 2011 Oct;55(10):4935-6
pubmed: 21768521
Infect Drug Resist. 2019 Feb 11;12:385-389
pubmed: 30809099
J Antimicrob Chemother. 2011 Sep;66(9):2002-5
pubmed: 21669947
Indian J Med Microbiol. 2012 Jan-Mar;30(1):93-5
pubmed: 22361769
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3249-50
pubmed: 26953204
Semin Respir Crit Care Med. 2015 Feb;36(1):74-84
pubmed: 25643272
Emerg Infect Dis. 2013 Oct;19(10):1699-701
pubmed: 24050656
Indian J Med Microbiol. 2018 Jan-Mar;36(1):32-36
pubmed: 29735823
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28584139
J Antimicrob Chemother. 2008 Dec;62(6):1241-4
pubmed: 18779256
Infect Immun. 2011 Oct;79(10):3895-904
pubmed: 21768279
Eur J Clin Microbiol Infect Dis. 2016 Mar;35(3):379-85
pubmed: 26740321
Antimicrob Agents Chemother. 2013 Oct;57(10):4736-42
pubmed: 23856781
Med J Aust. 2008 Feb 18;188(4):209-13
pubmed: 18279126
Pathog Glob Health. 2017 Jul;111(5):240-246
pubmed: 28670975
PLoS One. 2014 Aug 11;9(8):e104984
pubmed: 25110940
J Glob Antimicrob Resist. 2019 Mar;16:48-52
pubmed: 30244040
J Clin Microbiol. 2016 Dec 28;55(1):199-205
pubmed: 27807154